A Phase 3 interventional study of Serostim in Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome, sponsored by EMD Serono. Completed at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In Serono Study 24380, the antecedent protocol to Study 25373, patients were randomly assigned in a 3.0-to-1.0 ratio to Groups A and B. All patients in Group A received recombinant human growth hormone (Serostim®) 4 mg daily (the "induction" phase) for the first 12 weeks, and then were re-randomized to receive either placebo or Serostim 2 mg on alternate days (roughly equivalent to 1 mg daily) during Weeks 12-36 (the "maintenance" phase). All patients in Group B initially received placebo from baseline to Week 24, and then received Serostim® 4 mg daily from Weeks 24 to 36 (Grunfeld, 2007).
In the follow-up Study 25373, any subject who was enrolled in Serono Study 24380 and was assigned to Group A, who fully completed all study visits without a major protocol violation, was eligible to enroll to receive re-treatment with Serostim at a dose of 4 mg daily for 12 weeks. During study 25373, safety was monitored by recording of adverse events and measurement of urinalysis and laboratory blood tests to assess fasting glucose, fasting insulin, and routine biochemistry and hematology parameters. At Week 12 or at the time of study termination, subjects underwent re-assessment of body composition via anthropometry measurements and dual photon absorptiometry (DXA) scanning. In addition, at study termination, measurements of insulin-like growth factor I (IGF-I), insulin-like growth binding protein 3 (IGFBP-3), fasting lipid profile, and oral glucose tolerance testing were obtained.
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, subjects must either:
A pregnancy test is not required if the subject is post menopausal or surgically sterilized.
Exclusion Criteria:
Are unable to comply with the Concomitant Therapy restrictions as outlined in Section 5.5 and listed as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
Biological: Serostim
Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
Also known as: mammalian cell-derived recombinant human growth hormone, r hGH
Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan
Time frame: baseline to 12 weeks
Change From Baseline to Week 12 in Waist Circumference
Measured by anthropometry
Time frame: baseline to 12 weeks
Change From Baseline to Week 12 in Insulin-like Growth Factor I
Circulating levels of IGF-I
Time frame: baseline to 12 weeks
Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Insulin
Oral glucose tolerance testing
Time frame: baseline to 12 weeks
Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in 120 Minute Glucose
Oral glucose testing
Time frame: baseline to 12 weeks
Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Glucose
Oral glucose testing
Time frame: baseline to 12 weeks
Study Initiation Date: 03 Feb 2005 (date of first subject, first dose) Study Completion Date 04 Jan 2006 (date of last subject, last visit) 26 study centers in the United States and British Columbia participated in this study, with each center enrolling at least one subject into the study.
| Milestone | Serostim |
|---|---|
| Started | 126 |
| Completed | 110 |
| Not completed | 16 |
| Withdrew: Adverse event | 6 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Subject decision | 1 |
| Withdrew: Reason unspecified | 1 |
| kg | Serostim |
|---|---|
| Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan | -1.7 ± 1.4 |
Measured by anthropometry
| cm | Serostim |
|---|---|
| Change From Baseline to Week 12 in Waist Circumference | -1.5 ± 3.0 |
Circulating levels of IGF-I
| ng/mL | Serostim |
|---|---|
| Change From Baseline to Week 12 in Insulin-like Growth Factor I | 135.7 ± 210.7 |
Oral glucose tolerance testing
| mcIU/mL | Serostim |
|---|---|
| Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Insulin | 10.8 ± 22.3 |
Oral glucose testing
| mg/dL | Serostim |
|---|---|
| Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in 120 Minute Glucose | 11.7 ± 43.7 |
Oral glucose testing
| mg/dL | Serostim |
|---|---|
| Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Glucose | 4.5 ± 20.4 |
Collected over Adverse events were to be reported and collected on an ongoing basis from the day of written informed consent (baseline) until 4 weeks after the last investigational product administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Serostim | — | 2/126 (1.6%) | 89/126 (70.6%) |
| Event | Serostim |
|---|---|
| Cardiac failure congestiveCardiac disorders | 1/126 |
| DiverticulitisInfections and infestations | 1/126 |
| Event | Serostim |
|---|---|
| Oedema peripheralGeneral disorders | 31/126 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/126 |
| HypoaesthesiaNervous system disorders | 9/126 |
| Blood glucose increasedInvestigations | 8/126 |
| Joint swellingMusculoskeletal and connective tissue disorders | 8/126 |
| MyalgiaMusculoskeletal and connective tissue disorders | 8/126 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 8/126 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/126 |
| InsomniaPsychiatric disorders | 7/126 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 7/126 |
| Age, Categorical(Participants) | Serostim |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 126 |
| >=65 years | 0 |
| Age Continuous(years) | Serostim |
|---|---|
| Mean | 45.4 ± 7.1 |
| Sex: Female, Male(Participants) | Serostim |
|---|---|
| Female | 13 |
| Male | 113 |
| Region of Enrollment(participants) | Serostim |
|---|---|
| United States | 125 |
| Canada | 1 |
| Insulin-like Growth Factor I(ng/mL) | Serostim |
|---|---|
| Mean | 242.6 ± 132.8 |
| Oral Glucose Tolerance Testing - 120 Minute Glucose(mg/dL) | Serostim |
|---|---|
| Mean | 102.3 ± 35.7 |
| Oral Glucose Tolerance Testing - Fasting Glucose(mg/dL) | Serostim |
|---|---|
| Mean | 94.5 ± 14.7 |
| Oral Glucose Tolerance Testing - Fasting Insulin(mcIU/mL) | Serostim |
|---|---|
| Mean | 11.4 ± 13.6 |
2 further baseline measures are reported on the registry.
The record gives a start of Feb 2005, a primary completion of Jan 2006 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone